| Report ID | 277823 |
| Drug Identification Number | 02387034 |
| Brand name | ADREVIEW |
| Common or Proper name | Iobenguane (123I) Injection |
| Company Name | GE HEALTHCARE CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | IOBENGUANE 123 I |
| Strength(s) | 74MBq |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 5 mL |
| Anatomical Therapeutical Chemical (ATC) code | V09IX |
| Anatomical Therapeutical Chemical (ATC) description | |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | |
| Actual start date | 2026-02-11 |
| Estimated end date | 2026-02-17 |
| Actual end date | 2026-02-16 |
| Shortage status | Resolved |
| Updated date | 2026-02-17 |
| Company comments | Reason for shortage: equipment malfunction |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 1919 MINNESOTA COURT MISSISSAUGA, ONTARIO CANADA L5N 0C9 |
| Company contact information | 800-387-7146 [email protected] |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2026-02-17 | French | Compare |
| v3 | 2026-02-17 | English | Compare |
| v2 | 2026-02-11 | French | Compare |
| v1 | 2026-02-11 | English | Compare |
Showing 1 to 4 of 4